AbbVie Inc. (ABBV) Q1 2026 (USD): Adj. EPS 2.65 (exp. 2.59), Revenue 15bln (exp. 14.72bln). FY Adj. EPS view 14.08-14.28 (exp. 14.12)
Importance
Level 1
- Skyrizi revenue 4.48bln, Rinvoq estimate 2.12bln
- Humira revenue 688mln.
- Adj. GM 83.6%.
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ABBVIE INC#ABBV.US#GENERAL MOTORS CO#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#AUTOMOBILE MANUFACTURERS#BIOTECHNOLOGY#METALS & MINING#AUTOMOBILES#BIOTECHNOLOGY (GROUP)#AUTOMOBILES & COMPONENTS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ABBVIE INC#ABBV#GM#DXY#US EQUITIES